文献速递慢性肾脏病

肾脏病贫血治疗:超越促红细胞生成素

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin.
PubMed 文献 · Kidney Int Rep · 2021-06-09

综述指出促红细胞生成素虽降低输血率但未一致改善心血管结局或生活质量,达标血红蛋白13-14 g/dL增加心血管病残率和死亡率。缺氧诱导因子稳定剂三期试验显示升血红蛋白疗效与促红细胞生成素相当且无重大安全信号,但需长期随访;铁调素调节剂早期试验结果不一;SGLT2抑制剂可升高血红蛋白。

要点

  • 促红细胞生成素未一致改善心血管结局或生活质量,高血红蛋白目标增加风险
  • 缺氧诱导因子稳定剂三期试验升血红蛋白疗效与促红细胞生成素相当,需长期安全性随访
  • 铁调素调节剂早期试验安全性和疗效结果不一,SGLT2抑制剂可升高血红蛋白

核心结论

  • 缺氧诱导因子稳定剂升血红蛋白疗效与促红细胞生成素相当且暂无重大安全信号,但需长期随访确保安全。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 促红细胞生成素降低输血率但未一致改善心血管结局或生活质量。
  • 治疗至一般人群正常血红蛋白水平(13-14 g/dL)增加心血管病残率和死亡率。
  • 部分患者即使增加促红细胞生成素剂量仍未达到较低血红蛋白目标。
  • 缺氧诱导因子稳定剂三期试验显示升血红蛋白疗效与促红细胞生成素相当,暂无重大安全信号。
  • 铁调素调节剂早期临床试验安全性和疗效结果不一;SGLT2抑制剂在临床试验中与血红蛋白升高相关。

关键数值与推荐

  • 血红蛋白目标13-14 g/dL与较低目标相比增加心血管病残率和死亡率。

临床怎么用

  • 避免将血红蛋白治疗目标设定为一般人群正常水平(13-14 g/dL)。
  • 缺氧诱导因子稳定剂可有效升高血红蛋白,但需关注长期安全性。

局限性

  • 缺氧诱导因子稳定剂需长期随访研究和注册研究确保安全。
  • 铁调素调节剂早期试验安全性和疗效结果不一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia is common in patients with chronic kidney disease. Treatment with erythropoiesis-stimulating agents has decreased transfusion rates, but has not been consistently shown to improve cardiovascular outcomes or quality of life. Moreover, treatment to hemoglobin levels normal for the general population (13-14 g/dL) has resulted in increased cardiovascular morbidity and mortality versus lower hemoglobin targets, and some patients with chronic kidney disease do not reach these lower hemoglobin targets despite escalating doses of erythropoiesis-stimulating agents. The pathophysiology of anemia in patients with chronic kidney disease has been informed by the discovery of hypoxia-inducible factor and hepcidin pathways. Recent innovations in anemia treatment leverage knowledge of these pathways to effectively raise hemoglobin levels independent of erythropoiesis-stimulating agent administration. Several agents that stabilize hypoxia-inducible factor are undergoing or have completed phase 3 clinical trials. These agents appear to have equal efficacy as erythropoiesis-stimulating agents in raising hemoglobin levels and have not been associated with major safety signals to date. Because of the potential for off-target effects from non-anemia-related gene transcription by hypoxia-inducible factor stabilization, longer-term follow-up studies and registries will be needed to ensure safety. Agents that modulate hepcidin have undergone early clinical trials with mixed results regarding safety and efficacy in increasing hemoglobin levels. Sodium-glucose cotransporter 2 inhibitors, which also decrease hepcidin levels, have been associated with increased hemoglobin levels among patients with chronic kidney disease in clinical trials exploring proteinuria and kidney disease progression.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Wish JB. Treatment of Anemia in Kidney Disease: Beyond Erythropoietin. Kidney Int Rep. 2021. PMID: 34622095. doi:10.1016/j.ekir.2021.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。